Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discounts will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Bristol-Myers Squibb and the drug-development accelerator BioMotiv have launched Anteros Pharmaceuticals, a biotech firm developing drugs for fibrosis and inflammatory diseases. The start-up, which is based on technology developed at Yale University, is the first company to come out of a pact forged last fall between BMS and BioMotiv, which aims to advance discoveries made at research institutions. Bringing a molecule from the academic licensing stage to the clinic can cost $5 million to $7 million, a cost that the partners will share, BioMotiv CEO Satish Jindal says.
This article has been sent to the following recipient: